医药行业跟踪报告：中国创新ADC闪耀ASCOGU，长效三靶点减肥药二期临床成功

Investment Rating - The report assigns an "Outperform" rating for the industry, indicating a relative performance better than the benchmark index [2][4]. Core Insights - The pharmaceutical sector experienced a mild rebound, with the SW Pharmaceutical Biotechnology Index increasing by 0.50%, ranking 25th out of 31 in the primary industry indices. Notably, the medical consumables and other biological products sectors performed well, while CXO and chemical preparations lagged [2]. - Chinese innovation in ADC (Antibody-Drug Conjugates) was highlighted at the ASCO GU 2026 conference, showcasing promising clinical data for DB-1311 in metastatic castration-resistant prostate cancer, with a median radiographic progression-free survival (rPFS) of 11.3 months and a median overall survival (mOS) of 22.5 months [2]. - The success of the second-phase clinical trial for UBT251, a long-acting GLP-1/GIP/GCG tri-target agonist, was reported, showing an average weight loss of 19.7% in participants after 24 weeks of treatment. The company plans to initiate phase three clinical trials soon [2]. Summary by Sections Industry Performance - The A-share pharmaceutical sector's performance was subdued, with a 1.08% increase in the Shanghai and Shenzhen 300 Index during the week following the Spring Festival. The medical consumables sector saw a notable increase of 3.99% [2]. Clinical Developments - At the ASCO GU 2026 conference, over 70 research outcomes from Chinese experts were presented, with significant updates from several companies on ADC therapies, indicating a strong potential for ADC combined with immunotherapy in first-line cancer treatments [2]. - The report emphasizes the importance of ADCs, dual antibodies, small nucleic acids, and weight-loss drugs as key investment opportunities in the pharmaceutical sector [2]. Investment Recommendations - The report suggests that despite recent market fluctuations and a downturn in Hong Kong's innovative drug sector, the long-term trend of innovation in China's pharmaceutical industry remains positive. It highlights the potential for investment in ADCs, dual antibodies, and other high-growth areas [2].